Gizmodo reports there's been progress on a male birth-control gel "being developed with the help of several organizations, including the U.S. government's National Institute of Child Health and Human Development, part of the larger NIH." It's now being tested in a larger-scale Phase IIB trial, which involves around 400 couples. [Five milliliters of gel — about a teaspon — is applied to each shoulder blade once a day, reports NBC News.] That trial is still ongoing, but researchers have already begun to pore through some of the available data, which has provided encouraging results. In the summer of 2022, for instance, Diana Blithe, chief of the NICHD's Contraceptive Development Program, reported that the NES/T gel's efficacy rate so far appeared to be on par or even better than contraceptive hormonal options for women... The findings are still preliminary, and it will take more time for the full Phase II data to be collected and analyzed. But Blithe and her team have been encouraged by everything they've seen to date. In the team's early assessments, the gel appears to be both effective and safe, with minimal side effects for men taking it... Blithe and her colleagues are set to meet with the FDA next year about the steps needed to begin a larger Phase III trial and are still seeking a commercial partner to help bring the NES/T gel to the market. Initial findings also showed that the contraceptive worked faster than expected, Blithe said, according to NBC News. They add that at least three other companies are also working on male birth control: Also at the Boston conference on Sunday, YourChoice Therapeutics said a very small trial in the U.K. — just 16 men — showed that its nonhormonal pill, YCT-529, was safe and free of side effects. The San Francisco company's nonhormonal pill works by blocking the vitamin A receptor important for male fertility.YourChoice is planning a larger trial, according to CEO Akash Bakshi.

Read more of this story at Slashdot.

"Chinese scientists develop cure for diabetes," reads the headline from the world's second-most widely read English-language newspaper. ("Insulin patient becomes medicine-free in just 3 months.") The researchers' results were published earlier in May in Cell Discovery, and are now getting some serious scrutiny from the press. The Economic Times cites a University of British Columbia professor's assessment that the study "represents an important advance in the field of cell therapy for diabetes," in an article calling it a "breakthrough" that "marks a significant advancement in cell therapy for diabetes." Chinese scientists have successfully cured a patient's diabetes using a groundbreaking cell therapy... According to a South China Morning Post report, the patient underwent the cell transplant in July 2021. Remarkably, within eleven weeks, he no longer required external insulin. Over the next year, he gradually reduced and ultimately stopped taking oral medication for blood sugar control. "Follow-up examinations showed that the patient's pancreatic islet function was effectively restored," said Yin, one of the lead researchers. The patient has now been insulin-free for 33 months... The new therapy involves programming the patient's peripheral blood mononuclear cells, transforming them into "seed cells" to recreate pancreatic islet tissue in an artificial environment. Their article calls it "a significant medical milestone" — noting that 140 million people in China have diabetes (according to figures from the International Diabetes Federation). Thanks to long-time Slashdot reader AmiMoJo for sharing the news.

Read more of this story at Slashdot.

"A Swiss biocomputing startup has launched an online platform that provides remote access to 16 human brain organoids," reports Tom's Hardware: FinalSpark claims its Neuroplatform is the world's first online platform delivering access to biological neurons in vitro. Moreover, bioprocessors like this "consume a million times less power than traditional digital processors," the company says. FinalSpark says its Neuroplatform is capable of learning and processing information, and due to its low power consumption, it could reduce the environmental impacts of computing. In a recent research paper about its developments, FinalSpakr claims that training a single LLM like GPT-3 required approximately 10GWh — about 6,000 times greater energy consumption than the average European citizen uses in a whole year. Such energy expenditure could be massively cut following the successful deployment of bioprocessors. The operation of the Neuroplatform currently relies on an architecture that can be classified as wetware: the mixing of hardware, software, and biology. The main innovation delivered by the Neuroplatform is through the use of four Multi-Electrode Arrays (MEAs) housing the living tissue — organoids, which are 3D cell masses of brain tissue...interfaced by eight electrodes used for both stimulation and recording... FinalSpark has given access to its remote computing platform to nine institutions to help spur bioprocessing research and development. With such institutions' collaboration, it hopes to create the world's first living processor. FinalSpark was founded in 2014, according to Wikipedia's page on wetware computing. "While a wetware computer is still largely conceptual, there has been limited success with construction and prototyping, which has acted as a proof of the concept's realistic application to computing in the future." Thanks to long-time Slashdot reader Artem S. Tashkinov for sharing the article.

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Guardian: Proteins in the blood could warn people of cancer more than seven years before it is diagnosed, according to research [published in the journal Nature Communications]. Scientists at the University of Oxford studied blood samples from more than 44,000 people in the UK Biobank, including over 4,900 people who subsequently had a cancer diagnosis. They compared the proteins of people who did and did not go on to be diagnosed with cancer and identified 618 proteins linked to 19 types of cancer, including colon, lung, non-Hodgkin lymphoma and liver. The study, funded by Cancer Research UK and published in Nature Communications, also found 107 proteins associated with cancers diagnosed more than seven years after the patient's blood sample was collected and 182 proteins that were strongly associated with a cancer diagnosis within three years. The authors concluded that some of these proteins could be used to detect cancer much earlier and potentially provide new treatment options, though further research was needed.

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Guardian: A British toddler has had her hearing restored after becoming the first person in the world to take part in a pioneering gene therapy trial, in a development that doctors say marks a new era in treating deafness. Opal Sandy was born unable to hear anything due to auditory neuropathy, a condition that disrupts nerve impulses traveling from the inner ear to the brain and can be caused by a faulty gene. But after receiving an infusion containing a working copy of the gene during groundbreaking surgery that took just 16 minutes, the 18-month-old can hear almost perfectly and enjoys playing with toy drums. [...] The girl, from Oxfordshire, was treated at Addenbrooke's hospital, part of Cambridge university hospitals NHS foundation trust, which is running the Chord trial. More deaf children from the UK, Spain and the US are being recruited to the trial and will all be followed up for five years. [...] Auditory neuropathy can be caused by a fault in the OTOF gene, which makes a protein called otoferlin. This enables cells in the ear to communicate with the hearing nerve. To overcome the fault, the new therapy from biotech firm Regeneron sends a working copy of the gene to the ear. A second child has also recently received the gene therapy treatment at Cambridge university hospitals, with positive results. The overall Chord trial consists of three parts, with three deaf children including Opal receiving a low dose of gene therapy in one ear only. A different set of three children will get a high dose on one side. Then, if that is shown to be safe, more children will receive a dose in both ears at the same time. In total, 18 children worldwide will be recruited to the trial. The gene therapy -- DB-OTO -- is specifically for children with OTOF mutations. A harmless virus is used to carry the working gene into the patient.

Read more of this story at Slashdot.

For the second time, the disgraced former CEO of Theranos has had her federal prison sentence shortened. In July, it was reduced by two years. Now, 40-year-old Holmes is scheduled for release on August 16, 2032 instead of December 29, 2032 -- a reduction of more than four months. The Guardian reports: People incarcerated in the U.S. can have their sentences shortened for good conduct and for completing rehabilitation programs, such as a substance abuse program. The latest reduction of Holmes's sentence still meets federal sentencing guidelines. Those guidelines mandate that people convicted of federal offenses must serve at least 85% of their sentence, regardless of reductions for good behavior. In 2022, Holmes was sentenced to 11 years and three months in prison after being convicted on four counts of defrauding investors. She was also ordered to pay $452m in restitution to those she defrauded, but a judge delayed those payments due to Holmes's "limited financial resources." Holmes's lawyers have already begun attempts to get her conviction overturned. Oral arguments for her appeal are set to begin on June 11 in a federal appeals court in San Francisco, California, NBC News reported.

Read more of this story at Slashdot.

Crypto company Tether announced Monday that it has invested $200 million to acquire a majority stake in brain-computer interface company Blackrock Neurotech via its venture capital division Tether Evo. [The firm is not related to the asset management giant BlackRock.] CoinDesk reports: Blackrock Neurotech develops medical devices that are powered by brain signals and aims to help people impacted by paralysis and neurological disorders. The investment will fund the roll-out and commercialization of the medical devices and also for research and development purposes, the press release said. Tether is the company behind USDT, the largest stablecoin with a market cap of $110 billion. Recently, Tether established four divisions to expand beyond stablecoin issuance. "Tether has long believed in nurturing emerging technologies that have transformative capabilities, and the Brain-Computer-Interfaces of Blackrock Neurotech have the potential to open new realms of communication, rehabilitation, and cognitive enhancement," Paolo Ardoino, CEO of Tether, said in a statement.

Read more of this story at Slashdot.

A brain implant startup called Synchron is preparing to recruit patients for a large-scale clinical trial to seek commercial approval for its device. Reuters reports: Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview. "Part of this registry is to start to enable local physicians to speak to patients with motor impairment," he said. "There's a lot of interest so we don't want it to come in a big bottleneck right before the study we'll be doing." Synchron received U.S. authorization for preliminary testing in July 2021 and has implanted its device in six patients. Prior testing in four patients in Australia showed no serious adverse side effects, the company has reported. Synchron will be analyzing the U.S. data to prepare for the larger study, while awaiting authorization from the U.S. Food and Drug Administration to proceed, Oxley said. Synchron and the FDA declined to comment on the expected timing of that decision. The company aims to include patients who are paralyzed due to the neurodegenerative disease ALS (amyotrophic lateral sclerosis), stroke and multiple sclerosis, Oxley said. [...] Synchron's device is delivered to the brain via the large vein that sits next to the motor cortex in the brain instead of being surgically implanted into the brain cortex like Neuralink's. The FDA has asked Synchron to screen stroke patients using a non-invasive test to determine whether they would respond to an implant, Oxley said. "They want to expand the market to people who have had a stroke severe enough to cause paralysis because if limited to quadriplegia, the market is way too small to be sustainable," Kip Ludwig, former program director for neural engineering at the U.S. National Institutes of Health, said of Synchron. In 2020, Synchron reported that patients, opens new tab in its Australian study could use its first-generation device to type an average of 16 characters per minute. That's better than non-invasive devices that sit atop the head and record the electrical activity of the brain, which have helped people type up to eight characters per minute, but not the leap forward that is hoped for with an implant, Ludwig said. Oxley would not say whether typing has gotten faster or offer any other details from the ongoing U.S. trial. Reuters notes that Synchron's investors include billionaires Jeff Bezos and Bill Gates. It's competing with Elon Musk's Neuralink brain implant startup and claims it's farther along in the process of testing its device. Earlier this year, Neuralink said it implanted a chip in its first human patient. It later said the patient fully recovered and was able to control a computer mouse using their thoughts.

Read more of this story at Slashdot.

An anonymous reader quotes a report from InterestingEngineering: A Pittsburgh-based biotech company has started a one-of-a-kind trial in a patient with a failing liver. Their goal is to grow a functional second liver within the patient's body -- something never achieved before. If effective, it might be a life-saving therapy for those who require liver transplants but have to wait months for a compatible donor organ. LyGenesis is currently carrying out a trial in only one patient with end-stage liver disease (ESLD) to test the efficacy of their allogenic regenerative cell therapy. As per Nature, the experimental procedure was conducted in Houston on March 25. The report also states that the patient is "recovering well" after receiving the treatment. However, the formation of the new liver-like organ in the lymph node may take several months. Moreover, the individual will be kept on immunosuppressive drugs to prevent any initial rejection of the donor cells. The physicians will continue to monitor the patient's health closely. In this trial, scientists prepared donated hepatocyte cells for transplantation by suspending them in a solution. These cells were then transplanted into the patient's upper abdominal lymph nodes, which are tiny bean-shaped structures. These structures are an essential immune system component and filter waste from the body. Apart from the abdomen, lymph nodes are also found in the neck and chest. The team opted for a minimally invasive approach to inject the cells into the patient's lymph node via a catheter in the neck. "The lymph nodes then act as in vivo bioreactors, helping the hepatocytes to engraft, proliferate, and generate functional ectopic liver tissue," the press release noted. In simplest terms, these cells have the ability to multiply over the next several months. In a person with a failing liver, lymph nodes might operate as a second liver-like organ.

Read more of this story at Slashdot.